Skip to content

A feasibility study using secure utilization technologies for medical mydata in decentralized clinical trials

A feasibility study using secure utilization technologies for medical mydata in decentralized clinical trials: a multicenter and randomized controlled trial to evaluate the effect of green tea extract on cholesterol reduction

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CRIS
Registry ID
KCT0010989
Enrollment
12
Registered
2025-09-09
Start date
2025-10-10
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : The primary objective of this study is to evaluate the feasibility of applying homomorphic encryption and federated learning technologies to clinical trial screening and conduct.

Sponsors

Seoul National University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Adults aged between 19 and 75 years at the time of obtaining informed consent. (2) Individuals with available health examination records obtained within the past two years (from January 1 of the year two years prior to the assessment date up to the assessment date), at the time of de-identified preliminary risk assessment. (3) Individuals with a calculated cardiovascular disease risk probability of less than 10%, based on health examination records obtained within the past two years (from January 1 of the year two years prior to the assessment date up to the assessment date). (4) Individuals capable of installing and utilizing a mobile application. (5) Individuals who have received and fully understood detailed information about this clinical study, voluntarily decided to participate, and provided informed consent prior to screening procedures.

Exclusion criteria

Exclusion criteria: (1) Presence or history of clinically significant hepatic, renal, neurological, respiratory, endocrine, hematologic/oncologic, cardiovascular, urologic, or psychiatric disorders. (2) Known allergy to green tea extract. (3) Experience of symptoms such as nervousness or insomnia after consuming =100 mg of caffeine per day (equivalent to approximately one cup of coffee). (4) Aspartate aminotransferase or alanine aminotransferase levels exceeding 1.5 times the upper limit of normal. (5) Pregnant or lactating women, or women planning pregnancy. (6) Positive results on serological testing for hepatitis B virus, hepatitis C virus, or human immunodeficiency virus (HIV). (7) Current use or planned use of health supplements or medications related to cholesterol management during the intervention period. (8) Inability to refrain from consuming foods containing green tea or green tea extract during the intervention period. (9) Inability to maintain habitual levels of smoking, alcohol consumption, or physical activity during the intervention period. (10) Any other condition judged by the investigator to make the participant unsuitable for study participation.

Design outcomes

Primary

MeasureTime frame
Discrepancy between cardiovascular disease risk estimates derived through homomorphic encryption-based computation and those obtained by direct calculation performed by the investigator;Discrepancy between the cardiovascular disease risk prediction model constructed using federated learning and the model constructed by pooling raw data across sites.

Secondary

MeasureTime frame
Changes in total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides;Changes in cardiovascular disease risk probability

Countries

Korea, Republic of

Contacts

Public ContactJaegu Kang

Seoul National University Hospital

rkdworn489@snu.ac.kr+82-2-2072-4082

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026